Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Eli Lilly price target lowered to $973 from $995 at Guggenheim
Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...
Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...
Hims & Hers Health down 3% after BoA says Q4 revenue could be a miss
Hims & Hers Health is down ~3% in Friday morning trading after an analyst note from BofA Securities stated that the company's ...
Investor's Business Daily on MSN9h
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy ...
DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...
Baird Q4 2024 International And Global Growth Fund Commentary
In the fourth quarter of 2024, the Baird Chautauqua International Growth Fund Net Investor Class returned -4.31%, ...
US open: Stocks higher going into MLK Day long weekend
On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...
Morningstar11h
Global Sustainable Fund Flows: Q3 2024 in Review
In the third quarter of 2024, sustainable open-end and exchange-traded funds witnessed a surge in net new money, drawing in an estimated USD 10.4 billion. This represents a significant increase ...